ArticleViruses2018
Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans.
Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Ten years of Zika in Brazil: achievements, challenges and perspectives.Virology journal · 2026Review
- Zika virus-specific and orthoflavivirus-cross-reactive IgGs correlate with Zika virus seroneutralization depending on prior dengue virus infection.PLoS neglected tropical diseases · 2025Article
- Application of type-2 heptagonal fuzzy sets with multiple operators in multi-criteria decision-making for identifying risk factors of Zika virus.BMC infectious diseases · 2025Article
- Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies.PLoS neglected tropical diseases · 2024Article
- Comprehensive analysis of early T cell responses to acute Zika Virus infection during the first epidemic in Bahia, Brazil.PloS one · 2024Article
- Article
- Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model.Pathogens (Basel, Switzerland) · 2022Review
- Current Understanding of the Role of T Cells in Chikungunya, Dengue and Zika Infections.Viruses · 2022Review
- A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage.Cell reports · 2021Article
- Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay.Journal of immunological methods · 2021Article
- Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response.Frontiers in immunology · 2021Review
- Protection against dengue virus requires a sustained balance of antibody and T cell responses.Current opinion in virology · 2020Review
- Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.EBioMedicine · 2020Review
- Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design.Frontiers in immunology · 2020Review
- Cross-Protection of Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil.Emerging infectious diseases · 2019Article
- Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?Current opinion in immunology · 2019Review
- Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease.Tropical medicine and infectious disease · 2019Review
- Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Mouse Models of Heterologous Flavivirus Immunity: A Role for Cross-Reactive T Cells.Frontiers in immunology · 2019Review
- A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The high levels of dengue-virus (DENV) seroprevalence in areas where the Zika virus (ZIKV) is circulating and the cross-reactivity between these two viruses have raised concerns on the risk of increased ZIKV disease severity for patients with a history of previous DENV infections. To determine the role of DENV preimmunity in ZIKV infection, we analyzed the T- and B-cell responses against ZIKV in donors with or without previous DENV infection. Using peripheral blood mononuclear cells (PBMCs) from donors living in an endemic area in Colombia, we have identified, by interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay, most of the immunodominant ZIKV T-cell epitopes in the nonstructural (NS) proteins NS1, NS3, and NS5. Analyses of the T- and B-cell responses in the same donors revealed a stronger T-cell response against peptides conserved between DENV and ZIKV, with a higher level of ZIKV-neutralizing antibodies in DENV-immune donors in comparison with DENV-naïve donors. Strikingly, the potential for antibody-mediated enhancement of ZIKV infection was reduced in donors with sequential DENV and ZIKV infection in comparison with donors with DENV infection only. Altogether, these data suggest that individuals with DENV immunity present improved immune responses against ZIKV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.